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Abstract
Introduction Treatment of complex anterior circulation aneu-
rysms with flow diverters (FDs) has become common practice
in neurovascular centers. However, this treatment method for
posterior circulation aneurysms (PCAs) still remains
controversial.
Methods Through searches for reports on the treatment of
PCAs with FDs, we conducted a systematic review of the
literature on its clinical efficacy and safety using random-
effect binomial meta-analysis.
Results We included 14 studies, which reported on a total of
225 PCAs in 220 patients. Procedure-related good outcome
rate was 79 % (95 % confidence interval (CI), 72–84), with
significantly lower odds among patients with ruptured aneu-
rysms and basilar artery aneurysms. Procedure-related mortal-
ity rate was 15 % (95 % CI 10–21), with significantly higher
rates among patients with giant aneurysms and basilar artery
aneurysms. The rate of complete aneurysm occlusion at 6-
month digital subtraction angiography (DSA) was 84 %.
Ischemic stroke rate was 11 %. Perforator infarction rate was
7 %. Postoperative subarachnoid hemorrhage (SAH) rate was
3 %. Intraparenchymal hemorrhage (IPH) rate was 4 %.
Conclusions Flow diverter treatment of PCAs is an effec-
tive method, which provides a high rate of complete
occlusion at 6-month DSA. However, compared with an-
terior circulation aneurysms, patients with PCAs are at sig-
nificantly higher risk of mortality, ischemic stroke and per-
forator infarction. Our findings indicate that, in most clin-
ical centers, flow diverter treatment of PCAs should be
conducted in carefully selected patients with poor natural
history and no optimal treatment strategy. For ruptured and
giant basilar artery aneurysms, there is still no good treat-
ment option.
Keyword Endovascular treatment . Flow diverters .
Interventional neuroradiology . Posterior circulation
aneurysms
Flow diverters (FDs), as an addition to the endovascular
treatment options for intracranial aneurysms, have higher
surface coverage and lower porosity than conventional
intracranial stents. Their design focuses on diverting flow
from the aneurysm, thus creating an environment prone to
thrombosis. FDs may also provide scaffolding for endo-
thelialization and vessel wall healing. Treatment of com-
plex anterior circulation aneurysms, predominantly inter-
nal carotid artery (ICA) aneurysms, with FDs has become
common practice in neurovascular centers [1–3].
However, flow diverter treatment for posterior circulation
aneurysms (PCAs) still remains controversial because of
significantly higher rates of ischemic stroke and perforator
infarction than those observed for anterior circulation an-
eurysms [1–4].
In recent years, several studies have reported on the
safety and efficacy of flow diverter treatment for PCAs
[1–3, 5–15], but none have systematically evaluated the
rate of mortality, aneurysmal occlusion, and procedure-
related complications. It is therefore the aim of this
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systematic review and meta-analysis to provide a system-
atic understanding of the flow diverter treatment for PCAs,
which would help guide practitioners in selecting the best
therapy method for patients with complex PCAs.
Methods
We conducted PubMed, OVID, and Web of Science searches
to review all studies on the treatment of PCAs with FDs. In
Fig. 1 Selection of included
studies
Table 2 Characteristics of aneurysms and patients
Rate 95 % CI N
Posterior circulation aneurysm
Small 0.29 0.22–0.37 48
Large 0.48 0.40–0.56 79
Giant 0.23 0.17–0.30 38
Saccular 0.34 0.27–0.42 58
Not saccular 0.66 0.58–0.73 111
Ruptured 0.16 0.10–0.22 25
Unruptured 0.84 0.78–0.90 136
Retreatment 0.26 0.18–0.36 27
First treatment 0.74 0.64–0.82 75
Patient
Symptomatic 0.61 0.51–0.70 62
Asymptomatic 0.39 0.3–0.49 40

















Fig. 2 The location distribution of the aneurysms. BA basilar artery, SCA
superior cerebellar artery, AICA anterior inferior cerebellar artery, PICA
posterior inferior cerebellar artery, VA vertebral artery, VB vertebrobasilar
junction, PCA posterior cerebral artery
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brief, we used the keywords BPosterior Circulation
Aneurysms,^ BPED,^ Bpipeline embolization device,^ Bflow
diverter,^ Bdivert,^ Bdiversion,^ and Bpipeline.^ Inclusion
criteria were as follows: English language, ≥5 patients, studies
published between July 2005 and July 2015, and the presence
of data on procedure-related good outcome or mortality or
aneurysmal occlusion rate or postoperative complications.
The exclusion criteria were as follows: case reports, in vitro
or cadaveric studies, review articles, guidelines, technical
notes, and whether only a subset of patients of the total num-
ber of patients treated with FDs was analyzed. We also
searched the reference lists of all eligible studies and pertinent
publications for additional studies.
In the case of overlapping study populations, we tried to
exclude the possibility of individual patients being de-
scribed twice. When patients were included in multiple
studies, we contacted the study authors by e-mail to ex-
clude the duplicate cases. If the repetitive data could not
be definitively sorted out, the report with the higher num-
ber of patients and/or the longer follow-up was selected
[16]. Abstracts, methods, results, figures, and tables of
the full studies were searched for data on procedure-
related good outcome and mortality, aneurysmal occlusion
rates, and postoperative complications.
Epidemiological data included the number of patients and
aneurysms, the features of the aneurysms as well as the clin-
ical presentation (incidental, hemorrhagic, or symptomatic) of
the patients. Aneurysms were classified as small (<10 mm),
large (10 mm≤ aneurysm size≤25 mm), or giant (>25 mm).
The shape of aneurysms was classified as saccular and not
saccular. The state of aneurysms was divided into ruptured
and unruptured, herein ruptured aneurysms referred to the
ones received flow diverter treatment in the acute stage. The
term good outcome was defined as modified Rankin scale of
0–2 (mRS 0–2) and mortality as mRS 6. Aneurysmal occlu-
sion was defined as complete occlusion at 6-month digital
subtraction angiography (DSA). Postoperative complications
were analyzed with respect to ischemic stroke, perforator in-
fa rc t ion , subarachnoid hemorrhage (SAH), and
intraparenchymal hemorrhage (IPH). Subgroup analysis was
conducted between study outcomes and the characteristics of
aneurysms and patients.
Statistical analyses
Random-effect meta-analysis was performed on studies
that provided data on outcomes of patients who underwent
flow diverter treatment. We estimated from each study the
cumulative incidence (event rate) and 95 % CI for each
outcome. Subgroup analysis was carried out to evaluate
the impact of the preoperative conditions on the results,
which was presented as odds ratios (OR) with a 95 % CI.
Statistical heterogeneity across studies was assessed using
the I2 statistic. We evaluated potential publication bias by
using funnel plots.
Fig. 3 Forest plot and meta-analysis of procedure-related good outcome rate: ruptured aneurysms vs. unruptured aneurysms. M-H Mantel-Haenszel
method, CI confidence interval
Fig. 4 Forest plot and meta-analysis of procedure-related good outcome rate: basilar artery aneurysms vs. non basilar artery aneurysms.M-HMantel-
Haenszel method, CI confidence interval
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Results
Study selection
Our search strategy revealed a total number of 171 different
studies, 143 of which were excluded by title and abstract
screening. Of the 28 remaining studies, full texts were
accessed, and ten studies met our predefined inclusion criteria.
Two additional studies were found by considering the refer-
ence lists of the ten previously mentioned studies, and another
two additional studies were found from pertinent publications.
As a result, a total of 14 studies were included in the analysis
(Table 1), including seven prospective single-arm cohort stud-
ies and seven retrospective case series. Figure 1 presents a
flow chart illustrating the above search process.
Aneurysm and patient characteristics
A total of 220 patients with 225 PCAs (16 % [n=25, 95 % CI
10–22] ruptured, 84 % [n=136, 95 % CI 78–90] unruptured)
were included in the analyses. In terms of size, 29 % of the
aneurysms were classed as small (n=48, 95 % CI 22–37),
48 % (n=79, 95 % CI 40–56) were classed as large, and
23 % (n=38, 95 % CI 17–30) were giant aneurysms. Thirty-
four percent (n=58, 95 % CI 27–42) were saccular aneu-
rysms, and 66 % (n=111, 95 % CI 58–73) were not; 26 %
(n=27, 95 % CI 18–36) of the patients with aneurysms re-
ceived FD treatment as a retreatment. Of the 220 patients,
61 % (n=62, 95 % CI 51–70) were symptomatic, and the
other 39 % (n= 40, 95 % CI 30–49) were asymptomatic
(Table 2). The location distribution of the aneurysms was
showed in Fig. 2.
Study outcomes
Procedure-related good outcome rate was 79 % (95 % CI 72–
84), with significantly lower rates among patients with rup-
tured aneurysms and basilar artery aneurysms (OR 0.22, 95 %
CI 0.06–0.82 and OR 0.14, 95 % CI 0.04–0.54, respectively;
Figs. 3 and 4). Aneurysm size, aneurysm type, preoperative
symptoms, and prior treatment were not significantly associ-
ated with the rate of procedure-related good outcome (OR
0.99, 95 % CI 0.37–2.66; OR 6.20, 95 % CI 0.69–55.55;
OR 0.20, 95 % CI 0.04–1.07; and OR 1.72, 95 % CI 0.40–
7.34, respectively).
Procedure-related mortality rate was 15 % (95 % CI 10–
21), with significantly higher rates among patients with giant
aneurysms and basilar artery aneurysms (OR 3.77, 95 % CI
1.35–10.54 and OR 4.65, 95 % CI 1.24–17.40, respectively;
Figs. 5 and 6). Aneurysm state, aneurysm type, preoperative
symptoms, and prior treatment were not significantly associ-
ated with the rate of procedure-related mortality (OR 1.96,
95 % CI 0.28–13.62; OR 0.15, 95 % CI 0.02–1.13; OR
2.17, 95 % CI 0.17–27.91; and OR 0.33, 95 % CI 0.04–
2.55, respectively).
The rate of aneurysm complete occlusion at 6-month DSA
was 84 % (95 % CI 68–94), with no significant association
with aneurysm size (OR 3.60, 95 % CI 0.26–50.84). Ischemic
Fig. 5 Forest plot and meta-analysis of procedure-related mortality rate: giant aneurysms vs. small/large aneurysms.M-HMantel-Haenszel method, CI
confidence interval
Fig. 6 Forest plot and meta-analysis of procedure-related mortality rate: basilar artery aneurysms vs. non basilar artery aneurysms. M-H Mantel-
Haenszel method, CI confidence interval
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stroke rate was 11 % (95 % CI 7–17) with no significant
association with aneurysm size (OR 1.06, 95 % CI 0.26–
4.30). Perforator infarction rate was 7 % (95 % CI 3–13).
Postoperative SAH was 3 % (95 % CI 1–6 %). IPH rate was
4% (95%CI 1–8). The above data are summarized in Table 3.
Sensitivity analysis and publication bias
None of the analyses conducted exhibited heterogeneity ex-
cept for the analysis of procedure-related good outcome with
different size aneurysms (I2 =11 %), suggesting unexplained
minimal differences in study populations and procedures.
Funnel plot analyses on the statistically significant studies
are shown in Figs. 7, 8, 9, and 10, which indicated significant
publication bias.
Discussion
With recent advancements in neuroendovascular technology,
flow-diverting stents provided a new therapeutic option of
total intraluminal reconstruction for the treatment of intracra-
nial aneurysm. But compared with traditional clipping and
coiling, the use of FDs was restricted to giant and complex
aneurysms. Our meta-analysis included 225 aneurysms. Large
or giant aneurysms accounted for 71 % of the total, and 66 %
Table 3 Outcomes for endovascular treatment of posterior circulation aneurysms with FDs
Outcome Rate (95 % CI) OR 95 % CI I2 (%)
Procedure-related mortality (mRS 6) 0.15 (0.10–0.21)
Aneurysm size (giant vs. small/large)a Giant 0.37 (0.22–0.54) 3.77 1.35–10.54 0
Small/large 0.08 (0.04–0.15)
Aneurysm type (saccular vs. not saccular) Saccular 0 (0–0.12) 0.15 0.02–1.13 0
Not saccular 0.18 (0.10–0.28)
Aneurysm location (basilar artery vs. not basilar artery)a Basilar artery 0.25 (0.14–0.37) 4.65 1.24–17.40 0
Not basilar artery 0.07 (0.02–0.18)
Aneurysm state (rupture vs. unrupture) Rupture 0.14 (0.03–0.36) 1.96 0.28–13.62 0
Unrupture 0.11 (0.05–0.20)
Preoperative symptoms (with vs. without) With 0.18 (0.10–0.30) 2.17 0.17–27.91 0
Without 0 (0–0.10)
Prior treatment (retreatment vs. first treatment) Retreatment 0 (0–0.14) 0.33 0.04–2.55 0
First treatment 0.16 (0.08–0.26)
Procedure-related good outcome (mRS 0–2) 0.79 (0.72–0.84)
Aneurysm size (small vs. large/giant) Small 0.73 (0.57–0.86) 0.99 0.37–2.66 11
Large/giant 0.70 (0.60–0.79)
Aneurysm type (saccular vs. not saccular) Saccular 1 (0.83–1) 6.2 0.69–55.55 0
Not saccular 0.70 (0.57–0.81)
Aneurysm location (basilar artery vs. not basilar artery)a Basilar artery 0.55 (0.41–0.69) 0.14 0.04–0.54 0
Not basilar artery 0.95 (0.83–0.99)
Aneurysm state (rupture vs. unrupture)a Rupture 0.68 (0.46–0.85) 0.22 0.06–0.82 0
Unrupture 0.82 (0.74–0.88)
Preoperative symptoms (with vs. without) With 0.65 (0.52–0.77) 0.2 0.04–1.07 0
Without 0.97 (0.85–1)
Prior treatment (retreatment vs. first treatment) Retreatment 0.92 (0.73–0.99) 1.72 0.40–7.34 0
First treatment 0.73 (0.61–0.83)
Complete occlusion rate at 6-month DSA 0.84 (0.68–0.94)
Aneurysm size (small vs. large/giant) Small 1 (0.40–1) 3.6 0.26–50.84 0
Large/giant 0.6 (0.15–0.95)
Ischemic stroke 0.11 (0.07–0.17)
Aneurysm size (small vs. large/giant) Small 0.13 (0.04–0.29) 1.06 0.26–4.30 0
Large/giant 0.14 (0.07–0.24)
Perforator infarction 0.07 (0.03–0.13)
Subarachnoid hemorrhage 0.03 (0.01–0.06)
Intraparenchymal hemorrhage 0.04 (0.01–0.08)
CI confidence interval, mRS modified Rankin scale, DSA digital subtraction angiography, OR odds ratio
a Denotes statistically significant results
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of the aneurysms were classified as not saccular aneurysms,
including fusiform, dissecting, blister, and other complex an-
eurysms. Similar to conventional stents, flow-diverting stents
have also been controversial in the treatment of ruptured an-
eurysms because of the necessity of antiaggregation pre- and
post-operation. Of the 225 aneurysms reported here, 84 %
were unruptured. For ruptured aneurysms, there is still no
evidence-based concept or large agreement on antiplatelet
and anticoagulation schedule. Stephan et al. [7] gave patients
with ruptured aneurysms an intravenous bolus of heparin
(5000 IU) and aspirin (500 mg) at the start of the procedure.
After the procedure, intravenous heparin continued for 2 days;
double antiplatelet therapy with clopidogrel (75–150 mg/day)
and aspirin (81–325 mg/day) was continued for variable du-
ration. However, in other clinical centers, patients received a
loading dose of only 300 mg clopidogrel and 300 mg aspirin
6 h before aneurysm treatment [9], a loading dose of
clopidogrel 600 mg and aspirin 325 mg the night before sur-
gery [13], or 300/600 mg of clopidogrel on the day of the
procedure [2].
In our meta-analysis, 79 % of the patients showed a good
outcome. The rates ranged from 29 to 100 % [1, 2, 6–15],
highlighted by significantly lower rates in the patients with
ruptured and basilar artery aneurysms. Meanwhile, patients
with basilar artery aneurysms had a higher mortality rate.
The basilar artery is rich of perforator arteries, most of which
supply the cerebellum, brain stem, and other important struc-
tures. What is worse, these areas lack effective vascular com-
pensatory mechanisms. As a consequence, a relatively higher
perforator infarction rate was observed when FDs were placed
in the vascular lumen. The association between the location of
the aneurysms and the rate of perforator infarction during the
follow-up was not analyzed in our meta-analysis because of a
lack of information in many studies, but studies reporting the
Fig. 7 Procedure-related good
outcome rate: ruptured aneurysms
vs. unruptured aneurysms. SE
standard error, OR odds ratio
Fig. 8 Procedure-related good
outcome rate: basilar artery
aneurysms vs. non basilar artery
aneurysms. SE standard error, OR
odds ratio
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perforator infarction of basilar artery reported relatively higher
rates from 14 to 25 % [2, 7–9]. These results may account for
adverse outcomes in patients with basilar artery aneurysms.
Patients with ruptured aneurysms had worse preoperative sta-
tus compared to those with unruptured aneurysms. These fac-
tors likely lead to a lower good outcome rate, but not to a
higher mortality rate.
Mortality rate was another important indicator for evaluat-
ing the safety of flow diverter treatment for patients with
PCAs. Published mortality rates were variable, ranging from
0 to 57 % [1, 2, 5–15]. Our meta-analysis provided more
representative data on mortality rate, with significantly higher
rates among patients with giant and basilar artery aneurysms.
What accompanyingwith giant aneurysms are always rupture,
preoperative symptoms, higher rates of ischemic stroke, and
postoperative SAH [4]; none of which are conducive to the
recovery of patients. However, patients with ruptured
aneurysms or preoperative symptoms did not have a higher
mortality rate than patients without. In the meta-analysis re-
ported by Brinjikji et al. [4], 1451 patients with 1654 intracra-
nial aneurysms were treated with FDs, and the total mortality
rate was 4 %, which was significantly lower than that in the
patients with PCAs reported here.
The target of endovascular treatment is to prevent aneu-
rysms from either the first or a repeated rupture, so the occlu-
sion rate is the most important indicator to measure the effec-
tiveness of flow diverter treatment. We found a complete oc-
clusion rate of more than 80 % at 6-month DSA, which com-
pared favorably with that of stent-assisted [17] or balloon-
assisted embolization [18].
The main complications of FDs are ischemic stroke, perfo-
rator infarction, postoperative SAH, and IPH. They were not
rare in our meta-analysis, as only one study definitively re-
ported none of these complications [3]. Ischemic stroke was
Fig. 9 Procedure-related
mortality rate: giant aneurysms
vs. small/large aneurysms. SE
standard error, OR odds ratio
Fig. 10 Procedure-related
mortality rate: basilar artery
aneurysms vs. non basilar artery
aneurysms. SE standard error, OR
odds ratio
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the most common complication, followed by perforator in-
farction and IPH, and postoperative SAH. Among these com-
plications, the rates of ischemic stroke and perforator infarc-
tion were apparently higher than those reported for flow
diverter treatment of intracranial aneurysms, which were 6
and 3 % respectively [4]. High ischemic complications may
relate with the lack of optimal platelet inhibition, so platelet
function tests should be performed on all patients prior to the
procedure to make sure that the level of platelet inhibition was
adequate (>30 %) [3, 8]. What is more, adverse event rates
drop significantly with experience. Brinjikji et al. [4] reported
a significantly higher rate of ischemic stroke among patients
with large/giant aneurysms, and ascribed the cause to the lon-
ger operation time. We also analyzed the association between
the ischemic stroke rate and the size of the aneurysms, but did
not find similar results. This may be partly due to the small
number of cases analyzed.
Several limitations might have affected our results.
Publication bias is the most common systematic error of me-
ta-analysis, and it should be carefully considered here because
our results were based mostly on small studies. Compared
with large studies, small studies have reported more adverse
outcomes, and studies describing only a small number of pa-
tients may be more easily accepted for publication if they alert
for any adverse events [16]. Secondly, the available studies
were of poor quality, as approximately half were retrospective
case series. Thirdly, because studies with significant results
are more likely to be published in English, we only included
English language articles. As a consequence, it is possible that
some high quality studies in other languages might have been
excluded. Finally, the standard of selecting patients, pre- and
post-procedural antiplatelet/anticoagulation protocol, the
number and kind of the stents used, and personal experience
with stenting techniques varied in studies.
Conclusions
Flow diverter treatment of PCAs is an effective method which
provides a high rate of complete occlusion at 6-month DSA.
But compared with treatment of anterior circulation aneurysms,
it has significantly higher rates of mortality, ischemic stroke and
perforator infarction. Our findings indicate that, in most clinical
centers, flow diverter treatment of PCAs should be conducted
in carefully selected patients with poor natural history and no
optimal treatment strategy. For ruptured and giant basilar artery
aneurysms, there is still no good treatment option, and the
problem is unsolved. The findings reported herein suggest that
further well-designed prospective large studies are needed.
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